Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet ...

If we don’t have compassion, we really do need to question what that says about us as individuals and organisations ...

Spyre Therapeutics has appointed Kate Tansey Chevlen as Chief Commercial Officer.

Turn interaction into intelligence! Don’t miss this chance to lead the industry with our free pharma-exclusive webinar!